Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis
Management von Kindern mit heterozygoter familiärer Hypercholesterinämie weltweit: Metaanalyse
European Heart Journal Open · 24.12.2024 · 5 (1)
DOI: 10.1093/ehjopen/oeaf001 ↗Auf einen Blick
Die Metaanalyse bei 4.667 Kindern mit heterozygoter familiärer Hypercholesterinämie zeigte unter lipidsenkender Therapie bessere Lipidwerte als unter Kontrolle. LDL-C-Zielwerte wurden jedoch nur selten erreicht.
Fragestellung
Wie wirksam und sicher ist lipidsenkende Therapie bei Kindern mit heterozygoter familiärer Hypercholesterinämie, und wie oft wird das LDL-C-Ziel erreicht?
Methode
Metaanalyse von 41 Studien mit 4.667 pädiatrischen Patient:innen; Vergleich von LLT mit Kontrolle bzw. Vorher-nachher; medianes Follow-up 18,8 Monate.
Ergebnisse
Unter LLT sanken TC, LDL-C und TG und HDL-C stieg gegenüber Kontrolle [−1,75 mmol/L, −1,84 mmol/L, −0,11 mmol/L, +0,08 mmol/L; jeweils P < 0,001]. LDL-C sank um 33,44 %; 38,7 % erreichten das Ziel <3,5 mmol/L.
Einschränkungen
Unterschiede zwischen den untersuchten Ländern; Sicherheits- und Endokrinparameter sowie Abbruchraten wurden nur begrenzt berichtet.
Schlussfolgerung der Autor:innen
Trotz Wirksamkeit der LLT und seltener therapiebedingter Abbrüche wurden LDL-C-Ziele relativ selten erreicht; die Autor:innen betonen frühe Kombinationstherapie mit Statin und Ezetimib sowie PCSK9-Inhibitoren, falls verfügbar.
Kernaussagen
- LLT verbesserte TC, LDL-C, TG und HDL-C gegenüber Kontrolle
- 38,7 % erreichten das LDL-C-Ziel <3,5 mmol/L
- Große Länderunterschiede beim Erreichen des LDL-C-Ziels
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift European Heart Journal Open, online erschienen am 13.01.2025. Verfasst von Ibadete Bytyçi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Cardiology, University Clinical Centre of Kosovo, Mati I 37, 10000 Prishtina, Kosovo. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
Heterozygous familial hypercholesterolaemia (HeFH) is one of the most frequent monogenic disorders in the world, leading to premature atherosclerotic cardiovascular diseases. The aim of this meta-analysis was to evaluate the efficacy and safety of lipid-lowering therapy (LLT) and achievement of low density lipoprotein cholesterol (LDL-C) goal in children with HeFH. Methods and results The main endpoint was efficacy of goal achievement for LDL-C and other lipid parameters: total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein B, and lipoprotein(a), and the LLT safety [adverse events (AEs), including endocrine function, and growth indices]. The secondary endpoint was an effect of LLT on attainment of LDL-C goal treatment (<3.5 mmol/L/130 mg/dL). A total of 41 studies with 4667 paediatric patients at mean age 12.08 ± 2.4 years were included. Seventeen reported the efficacy and safety of LLT therapy compared to control, while the remaining assessed LLT through pre- and post-treatment. At median follow-up of 18.8 months, the group on LLT had significantly higher mean reductions of TC, LDL-C, TG, and increased HDL-C compared to control [−1.75 mmol/L (−67.7 mg/dL), −1.84 mmol/L (−71.2 mg/dL), −0.11 mmol/L (−9.74 mg/dL), 0.08 mmol/L (3.1 mg/dL), respectively, P < 0.001 for all]. In the subgroup analysis according to different types of LLT, we observed a significantly higher mean reduction of LDL-C by statin combined with ezetimibe treatment, followed by statins in monotherapy, PCSK9 inhibitors, and monotherapy with ezetimibe [−2.48 mmol/L (−95.9 mg/dL), −2.16 mmol/L (−83.5 mg/dL), −2.03 mmol/L (−78.5 mg/dL), and −1.50 mmol/L (−58 mg/dL), respectively, test for overall effect: P < 0.001]. The pooled LDL-C was reduced by 33.44% [−2.14 mmol/L (−82.8 mg/dL), P < 0.001] and failed to reach the goal treatment (<3.5 mmol/L) by 12.6% (95% CI, 12.4–12.9%). A total of 38.7% of children achieved the LDL-C goal, 23.9% fell short by up to 10%, 10.7% experienced moderate failure (were over the LDL-C target between >10% and 20%), and 26.7% failed by more than 20% to reach the LDL-C target. When comparing different regions, only Sweden and Greece achieved the LDL-C goal < 3.5 mmol/L in the follow-up. Netherlands, Norway, Poland, USA, UK, France, Spain, Belgium, and Austria required 2.2%, 3.4%, 3.5%, 8.9%, 10.2%, 11.2%, 11.2%, 15%, and 19.4% additional reduction in LDL-C respectively to achieve the LDL-C goal of < 3.5 mmol/L. All other countries required over 20% additional reduction in LDL-C to achieve the LDL-C goal. For other investigated countries, over 20% mean LDL-C reduction was required. All parameters related to endocrine function and demographic indices were unaffected by LLT therapy (P > 0.05). The AEs were not reported significantly higher when compared to the control, and the prevalence of therapy discontinuation was only 0.8%.
Conclusion
Despite the efficacy of LLT in children with HeFH and the low occurrence of discontinuation-related adverse events, achieving LDL-C treatment goals was relatively rare, with large differences between the investigated countries. These results underscore the importance of considering early combination therapy of statins and ezetimibe, and PCSK9 inhibitors (if available) to attain LDL-C goals effectively.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Cardiology, University Clinical Centre of Kosovo, Mati I 37, 10000 Prishtina, Kosovo.
- Department of Public Health and Clinical Medicine, Umeå University, 90187 Umeå, Sweden.
- Medical Faculty, University of Prishtina, Rrethi i Spitalit, pn., 10000 Prishtina, Kosovo.
- Riinvest College, Lidhja e Prizrenit no.56, Prishtina, Kosovo.
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, 93-338 Lodz, Poland.
- Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Rzgowska 281/289, 93-338 Lodz, Poland.
ORCID-Profile: Gani Bajraktari, Maciej Banach
Zitieren
APA
Bytyçi, I., Bytyqi, S., Lewek, J., Surma, S., Bajraktari, G., Henein, M., Sahebkar, A., Al-Khnifsawi, M., Gouni-Berthold, I., Pećin, I., Toth, P. P., Paneni, F., Katsiki, N., Escobar, C., Lavie, C. J., Gaita, D., Santos, R. D., Cicero, A. F. G., Bielecka-Dabrowa, A., …, & Banach, M. (2024). Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis. European Heart Journal Open, 5(1). https://doi.org/10.1093/ehjopen/oeaf001
Vancouver
Bytyçi I, Bytyqi S, Lewek J, Surma S, Bajraktari G, Henein M, et al. Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis. European Heart Journal Open. 2024;5(1). doi:10.1093/ehjopen/oeaf001
BibTeX
@article{Bytyi2024,
author = {Bytyçi, Ibadete and Bytyqi, Sefer and Lewek, Joanna and Surma, Stanislaw and Bajraktari, Gani and Henein, Michael and Sahebkar, Amirhossein and Al-Khnifsawi, Mutaz and Gouni-Berthold, Ioanna and Pećin, Ivan and Toth, Peter P and Paneni, Francesco and Katsiki, Niki and Escobar, Carlos and Lavie, Carl J and Gaita, Dan and Santos, Raul D and Cicero, Arrigo F G and Bielecka-Dabrowa, Agata and Ahmed, Ali and Banach, Maciej},
title = {Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis},
journal = {European Heart Journal Open},
year = {2024},
volume = {5},
number = {1},
doi = {10.1093/ehjopen/oeaf001}
}
EUVIMED